Treatment of type 2 diabetes

Acta Clinica Belgica

Volumn 58, Issue 5, 2003, Pages 318-324

  Scheen, André J ^a,b  

^a CHU SART TILMAN   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Cardiovascular risk; Combined therapy; Insulin; Oral antidiabetic agents; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ACETYLSALICYLIC ACID; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CARBUTAMIDE; CHLORPROPAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; FIBRINOGEN; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLIQUIDONE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TOLAZAMIDE; TOLBUTAMIDE; TRIACYLGLYCEROL;

AGE; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMORBIDITY; CONFERENCE PAPER; DIABETIC DIET; DRUG CHOICE; DRUG COST; DRUG SAFETY; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN RELEASE; LIFESTYLE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ISLET BETA CELL; PHYSICAL ACTIVITY; QUALITY OF LIFE; WEIGHT REDUCTION;

EID: 0348142187     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: 10.1179/acb.2003.58.5.010     Document Type: Conference Paper

References (25)

1. Massi-Benedetti M (Ed). The cost of diabetes type II in Europe. The CODE-2 study. Diabetologia 2002; 45 (Suppl 1): S1-S28.
2. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 2003; 46: 3-19.
3. Turner RC, Cull CA, Frighi V, Holman RR. Glycaemic control with diet, sulfonylurea, metformin or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999; 281: 2005-12.
4. Scheen AJ, Lefèbvre PJ. Le diabète non insulinodé pendant: de la physiopathologie au traitement. Bull Mem Acad Roy Med Belg 1996; 151: 395-405.
5. Scheen AJ, Lefèbvre PJ. Oral antidiabetic agents: a guide to selection. Drugs 1998; 55: 225-36.
6. Scheen AJ. Current management of coexisting obesity and type 2 diabetes. Drugs 2003; 63: 1165-84.
7. Scheen AJ. Insulin resistance syndrome and atherosclerotic cardiovascular disease. Acta Clin. Belg 1996; 51: 65-9.
8. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-93.
9. Scheen AJ. Non-insulin-dependent diabetes mellitus in the elderly. Baillière's Clin Endocrinol Metab 1997; 11: 388-406.
10. Winocour PH. Effective diabetes care: a need for realistic targets. BMJ 2002; 324: 1577-80.
11. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.
12. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-65.
13. Scheen AJ, Lefèbvre PJ. Treatment of diabetes mellitus. In: Clinical Pharmacology, (Ed: C. Sirtori), Mc Graw Hill, London, 2000, 685-98.
14. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 2003; 26 (Suppl 1): S33-S50.
15. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999; 131: 281-303.
16. Scheen AJ. Drug treatment of non-insulin-dependent diabetes mellitus in the 1990s: achievements and future developments. Drugs 1997; 54: 355-68.
17. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002; 287: 360-72.
18. European Diabetes Policy Group. A desktop guide to Type 2 diabetes mellitus. Diabet Med 1999; 16: 716-30.
19. Edelman SV, Henry RR. Insulin therapy for normalizing glycosylated hemoglobin in Type II diabetes. Diabetes Rev 1995; 3: 308-34.
20. Scheen AJ, Castillo MJ, Lefèbvre PJ. Combination of oral antidiabetic drugs and insulin in the treatment of non-insulin-dependent diabetes. Acta Clin Belg 1993; 48: 259-68.
21. Yki-Järvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care 2001; 24: 758-67.
22. Campbell IA. Antidiabetic drugs present and future: will improving insulin resistance benefit cardiovascular risk in type 2 diabetes mellitus? Drugs 2000; 60: 1017-28.
23. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). BMJ 1998; 317: 703-13.
24. Arauz-Pacheco C, Parrott MA, Raskin P. The treatment of hypertension in adult patients with diabetes mellitus. Diabetes Care 2002; 25: 134-47.
25. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361: 2005-16.